Physician profile
Michelle Thomas
NPI 1306994090
$36,146.43
in general payments reported to CMS, 2019-2025
15 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,798 · 2022: $4,472 · 2023: $7,230 · 2024: $7,874 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $5,802 · Food and Beverage: $3,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,925.00 |
| Travel and Lodging | $5,802.08 |
| Food and Beverage | $3,149.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34,727.60 | 2021-2025 | Biktarvy, Sunlenca |
| Viiv Healthcare Company | $500.35 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $159.49 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $151.10 | 2021-2023 | Delstrigo, Pifeltro, Dificid |
| Genentech USA, INC. | $125.00 | 2021 | |
| Janssen Products, LP | $99.00 | 2021 | |
| Novo Nordisk INC | $81.81 | 2023 | Wegovy |
| Neurocrine Biosciences, INC. | $70.72 | 2022-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $56.51 | 2022-2023 | Abilify Maintena |
| Indivior INC. | $49.01 | 2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $38.19 | 2022-2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Glaxosmithkline, LLC. | $28.41 | 2022 | |
| Qiagen, LLC | $17.54 | 2021 | |
| Janssen Biotech, INC. | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.